Rankin Aubrey

Average Profitability
14.59%
Insider Buys Quantity
1
Insider Buys Sum
$432,876.00
Insider Sells Quantity
10
Insider Sells Sum
$8.67M

Insider Activity of Rankin Aubrey

The largest purchase of all time was on 2021-12-03 and amounted to 30000 shares of Revance Therapeutics, Inc. for $432,876.

The largest sale of all time was on 2021-07-26 and amounted to 55382 shares of Revance Therapeutics, Inc. for $1.65M.

Biography of Rankin Aubrey

No biography is available at this moment.

2021-12-03PurchaseRevance Therapeutics, Inc.
RVNC
President, Innovation & Tech
30,000
0.0439%
$14.43$432,876+14.59%
2021-08-16SaleRevance Therapeutics, Inc.
RVNC
President, Innovation & Tech
9,364
0.0137%
$26.34$246,659-41.33%
2021-07-28SaleRevance Therapeutics, Inc.
RVNC
President, Innovation & Tech
54,332
0.0801%
$30.06$1.63M-48.05%
2021-07-26SaleRevance Therapeutics, Inc.
RVNC
President, Innovation & Tech
55,382
0.0818%
$29.72$1.65M-47.39%
2021-04-05SaleRevance Therapeutics, Inc.
RVNC
President, Innovation & Tech
2
<0.0001%
$28.28$57-8.56%
2021-03-04SaleRevance Therapeutics, Inc.
RVNC
President, Innovation & Tech
33,119
0.0492%
$25.43$842,216+5.45%
2021-02-01SaleRevance Therapeutics, Inc.
RVNC
President, Innovation & Tech
33,119
0.0489%
$25.95$859,438+3.49%
2020-12-30SaleRevance Therapeutics, Inc.
RVNC
President, Innovation & Tech
33,119
0.0515%
$27.82$921,212-1.68%
2020-11-30SaleRevance Therapeutics, Inc.
RVNC
President, Innovation & Tech
33,119
0.0517%
$23.85$789,888+15.16%
2020-10-29SaleRevance Therapeutics, Inc.
RVNC
President, Innovation & Tech
33,119
0.0526%
$26.15$865,949+6.88%
2020-09-28SaleRevance Therapeutics, Inc.
RVNC
President, Innovation & Tech
33,119
0.0551%
$26.18$867,055+6.91%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.